Exelixis, Inc. $EXEL Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D decreased its position in Exelixis, Inc. (NASDAQ:EXEL) by 1.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,275 shares of the biotechnology company’s stock after selling 1,248 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Exelixis were worth $3,847,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Fuller & Thaler Asset Management Inc. boosted its holdings in Exelixis by 2.2% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company’s stock worth $287,794,000 after purchasing an additional 164,134 shares during the period. AQR Capital Management LLC lifted its position in shares of Exelixis by 73.8% in the 1st quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after buying an additional 2,926,884 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Exelixis by 40.2% in the 1st quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock valued at $205,725,000 after buying an additional 1,596,948 shares during the period. Nuveen LLC bought a new stake in shares of Exelixis during the 1st quarter valued at about $123,310,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Exelixis by 2.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,321,407 shares of the biotechnology company’s stock worth $122,626,000 after acquiring an additional 69,054 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. The Goldman Sachs Group assumed coverage on Exelixis in a research note on Wednesday, September 17th. They issued a “buy” rating and a $47.00 target price for the company. Leerink Partners upgraded Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a research report on Tuesday, October 21st. Zacks Research lowered Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. JMP Securities reissued a “market outperform” rating and set a $50.00 price target on shares of Exelixis in a report on Tuesday, July 29th. Finally, Citigroup restated a “market outperform” rating on shares of Exelixis in a research report on Tuesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $44.53.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $39.99 on Tuesday. Exelixis, Inc. has a 1 year low of $28.05 and a 1 year high of $49.62. The firm has a market cap of $10.77 billion, a P/E ratio of 19.23, a PEG ratio of 0.78 and a beta of 0.38. The stock has a fifty day moving average price of $38.72 and a two-hundred day moving average price of $40.15.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business had revenue of $568.26 million during the quarter, compared to analyst estimates of $574.36 million. During the same quarter in the prior year, the firm posted $0.84 earnings per share. The company’s revenue was down 10.8% on a year-over-year basis. On average, research analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.